, 2009). Our results uncover a new transcription-independent

mechanism by which calcineurin mediates neuronal responses to extrinsic neurotrophic cues. We found that, over 24 hr, axon growth in response to NGF acting locally at axon terminals in sympathetic and DRG sensory neurons was significantly attenuated by calcineurin inhibition but not transcriptional blockade. Thus, we favor the hypothesis that calcineurin-mediated TrkA trafficking Tanespimycin in vitro influences early growth events through local axonal mechanisms. Currently, it remains unclear as to why TrkA endocytosis might be selectively required for NGF-mediated, but not NT-3-mediated, axonal growth in sympathetic neurons. One possible explanation might be that, because NGF uniquely promotes TrkA endocytosis in nerve terminals for carrying retrograde survival signals back to neuronal soma, this process has been co-opted

for local control of NGF-mediated axonal growth, via mechanisms that remain to be identified. It is possible that TrkA localization to endocytic vesicles might enhance downstream signaling, perhaps by prolonging association with downstream signaling effectors, spatially concentrating activated receptors, or by recycling receptors back to the membrane for repeated interaction with ligand. Our findings that NGF does not induce NFAT activation within 24 hr in sympathetic and DRG sensory neurons do not preclude a requirement for calcineurin/NFAT-mediated transcriptional activity in supporting long-term axonal growth. Although we found that transcriptional activity is Selleck Alpelisib not required for NGF-mediated axonal growth over the first 24 hr, continued axonal growth after 24 hr requires new gene expression. This may reflect a specific role for NGF-mediated transcriptional responses, acting either via the calcineurin/NFAT, MAPK/SRF (Wickramasinghe et al., 2008), or CREB pathways (Lonze et al., 2002). Alternatively, this may reflect a general loss of proteins important for axonal growth during the extended treatments with transcriptional inhibitors. Together with the previously published almost study by Graef et al. (2003), our findings

might reflect a biphasic mechanism of action for calcineurin in neurotrophin-mediated axonal growth. Thus, calcineurin might act early, via trafficking of TrkA receptors in axons and local activation of growth-promoting pathways, and at later stages, via activation of NFAT-mediated transcription. NFATc2/c3/c4 triple null mice die early, at embryonic day E11.5 ( Graef et al., 2001), prior to the formation of sympathetic axons and innervation of target tissues. Further studies using mice with conditional deletion of NFAT isoforms will be needed to elucidate the contribution of NFAT-mediated transcription to the developing sympathetic nervous system. Nevertheless, our results indicate that NFAT transcription factors are not the sole targets of calcineurin relevant for neurotrophin-mediated axon growth.